Kanada - angielski - Health Canada

jamp pharma corporation - ticagrelor - tablet - 60mg - ticagrelor 60mg

Kanada - angielski - Health Canada

jamp pharma corporation - ticagrelor - tablet - 90mg - ticagrelor 90mg

Izrael - angielski - Ministry of Health

astrazeneca (israel) ltd - ticagrelor - film coated tablets - ticagrelor 60 mg - ticagrelor - brilinta, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with - acute coronary syndromes (acs) or- a history of myocardial infarction (mi) and a high risk of developing an atherothrombotic event (see sections 4.2 and 5.1).limitations of use: 90 mg twice daily during the first year after an acs event followed by 60 mg twice daily for additional 2 years.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - ticagrelor (unii: glh0314rvc) (ticagrelor - unii:glh0314rvc) - ticagrelor 90 mg - brilinta is indicated to reduce the risk of cardiovascular (cv) death, myocardial infarction (mi), and stroke in patients with acute coronary syndrome (acs) or a history of mi. for at least the first 12 months following acs, it is superior to clopidogrel. brilinta also reduces the risk of stent thrombosis in patients who have been stented for treatment of acs [see clinical studies (14.1)] . brilinta is indicated to reduce the risk of a first mi or stroke in patients with coronary artery disease (cad) at high risk for such events [see clinical studies (14.2)] . while use is not limited to this setting, the efficacy of brilinta was established in a population with type 2 diabetes mellitus (t2dm). brilinta is indicated to reduce the risk of stroke in patients with acute ischemic stroke (nih stroke scale score ≤5) or high-risk transient ischemic attack (tia) [see clinical studies (14.3)] . brilinta is contraindicated in patients with a history of intracranial hemorrhage (ich) because of a high risk of recurrent i

Australia - angielski - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - ticagrelor, quantity: 90 mg - tablet, film coated - excipient ingredients: hyprolose; purified talc; iron oxide yellow; macrogol 400; hypromellose; mannitol; calcium hydrogen phosphate dihydrate; titanium dioxide; magnesium stearate; sodium starch glycollate type a - brilinta, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

chiesi usa, inc. - cangrelor (unii: 6aq1y404u7) (cangrelor - unii:6aq1y404u7) - cangrelor 50 mg - kengreal is indicated as an adjunct to percutaneous coronary intervention (pci) to reduce the risk of periprocedural myocardial infarction (mi), repeat coronary revascularization, and stent thrombosis (st) in patients who have not been treated with a p2y12 platelet inhibitor and are not being given a glycoprotein iib/iiia inhibitor [see clinical studies ( 14.1 )]. kengreal is contraindicated in patients with significant active bleeding [see warnings and precautions ( 5.1 ) and adverse reactions ( 6.1 )] . kengreal is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to kengreal or any component of the product [see adverse reactions ( 6.1 )] . risk summary there are no available data on cangrelor use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. untreated myocardial infarction can be fatal to the pregnant women and fetus (see clinical considerations ). in animal reproduction studies, continuous inf

Australia - angielski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ticagrelor, quantity: 90 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; hypromellose; mannitol; magnesium stearate; hyprolose; iron oxide yellow; purified talc; macrogol 400; titanium dioxide - apo-ticagrelor, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ticagrelor 60mg - film coated tablet - 60 mg - active: ticagrelor 60mg excipient: calcium hydrogen phosphate magnesium stearate mannitol opadry yellow 00f520007 povidone purified water sodium starch glycolate - ticagrelor-teva, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke), - in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg) and - in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ticagrelor 90mg - film coated tablet - 90 mg - active: ticagrelor 90mg excipient: calcium hydrogen phosphate magnesium stearate mannitol opadry yellow 00f520007 povidone purified water sodium starch glycolate - ticagrelor-teva, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke), - in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg) and - in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

viatris limited - ticagrelor 90mg - film coated tablet - 90 mg - active: ticagrelor 90mg excipient: calcium hydrogen phosphate dihydrate croscarmellose sodium hypromellose magnesium stearate mannitol microcrystalline cellulose opadry yellow 32k520044 - ticagrelor mylan, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).